News
The company is not developing an mRNA vaccine, but had been using one as the control in a 10,000-subject Phase IIb trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback